Q2 2025 EPS Estimates for Alkermes plc (NASDAQ:ALKS) Decreased by Analyst

Alkermes plc (NASDAQ:ALKS) – Investment analysts at Zacks Research lowered their Q2 2025 earnings per share estimates for shares of Alkermes in a research report issued to clients and investors on Wednesday, October 9th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.44 for the quarter, down from their prior forecast of $0.45. The consensus estimate for Alkermes’ current full-year earnings is $2.36 per share. Zacks Research also issued estimates for Alkermes’ Q3 2025 earnings at $0.50 EPS, Q4 2025 earnings at $0.51 EPS, FY2025 earnings at $1.84 EPS, Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.59 EPS and FY2026 earnings at $2.03 EPS.

ALKS has been the subject of several other research reports. Robert W. Baird boosted their target price on shares of Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. StockNews.com raised Alkermes from a “hold” rating to a “buy” rating in a research note on Sunday, July 28th. HC Wainwright upped their target price on Alkermes from $35.00 to $37.00 and gave the company a “neutral” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. lifted their price target on Alkermes from $31.00 to $32.00 and gave the company a “neutral” rating in a report on Thursday, July 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $48.00 target price on shares of Alkermes in a report on Thursday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $36.70.

Alkermes Stock Up 5.6 %

ALKS stock opened at $28.91 on Monday. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.99 and a quick ratio of 2.61. The company’s 50 day simple moving average is $27.61 and its 200-day simple moving average is $25.77. Alkermes has a 12 month low of $22.01 and a 12 month high of $32.88. The firm has a market capitalization of $4.89 billion, a PE ratio of 11.43, a P/E/G ratio of 0.56 and a beta of 0.46.

Alkermes (NASDAQ:ALKS) last released its earnings results on Wednesday, July 24th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. The company had revenue of $399.13 million during the quarter, compared to the consensus estimate of $393.30 million. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. Alkermes’s quarterly revenue was down 35.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.38 earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Alkermes by 12.3% in the fourth quarter. Vanguard Group Inc. now owns 20,955,454 shares of the company’s stock valued at $581,304,000 after acquiring an additional 2,288,185 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Alkermes by 29.8% during the fourth quarter. Wellington Management Group LLP now owns 15,241,470 shares of the company’s stock valued at $422,798,000 after purchasing an additional 3,494,678 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Alkermes by 421.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,326,256 shares of the company’s stock worth $225,393,000 after purchasing an additional 6,730,671 shares during the period. Pacer Advisors Inc. grew its holdings in Alkermes by 31.8% during the second quarter. Pacer Advisors Inc. now owns 5,640,642 shares of the company’s stock worth $135,939,000 after acquiring an additional 1,362,079 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Alkermes by 14.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,884,012 shares of the company’s stock worth $69,507,000 after purchasing an additional 371,039 shares during the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.